There is evidence that the ST6Gal I enzyme activity is significantly higher than the ST6Gal II one in colorectal cancers (CRC) [4], and that one of their most significant glycosylation changes is the elevation of ST6Gal I activity in tumour tissues, when compared with the surrounding healthy mucosa [5]. This evidence concerns the gene ST6GAL1 and colorectal carcinoma.